MPR Weekly Dose

MPR Weekly Dose 94 - COVID Vaccine Booster Doses; Pediatric Vaccine Trial; Parental Vaccine Hesitancy; Remdesivir and Hospitalization Risk; Atopic Dermatitis Treatment

Sep 24, 2021

The Pfizer-BioNTech vaccine gets Emergency Use Authorization for booster dose in certain individuals; A smaller dose appears safe and effective in children; Janssen share booster data for their vaccine; A survey sheds light on parents’ thoughts on child COVID vaccination; Remdesivir efficacy data in COVID-19 patients,...

MPR Weekly Dose 93 - Mandatory Opioid Prescriber Education; Rise in Delta-8 THC Products; Brukinsa and Exkivity Approved; Warning Letters for Supplement Companies

Sep 17, 2021

This week the FDA weigh up mandatory education for opioid prescribers; There’s an increase in the sale of strong psychoactive THC products; Brukinsa and Exkivity gain approvals for lymphoma and NSCLC, respectively; And a number of supplement companies received FDA warning letters.

MPR Weekly Dose 92 - AAP Vaccination Guidance; Moderna Booster; JAK Inhibitor Warnings; New Migraine Treatment Nasal Spray; Hold Placed on Phenylketonuria

Sep 10, 2021

This week we have news on pediatric influenza vaccine guidance; Moderna submit data for their COVID-19 booster dose; There’s new FDA warnings for some JAK inhibitors; Trudhesa nasal spray is approved; And the FDA places a clinical hold on a gene therapy for phenylketonuria.